Conceptio
›
Archive
›
HAL (France)
HAL (France)
open access
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
0
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Elaboration and profiling of the first OSBP degrader issued from natural Schweinfurthins
#1000784
Stencilled Musik Books in France : techniques, inventories, ateliers, 1669–1841, Introduction
#1000785
Logarithm laws for equilibrium states in negative curvature
#1000786
Education and transfer of water competencies: An ecological dynamics approach
#1000787
Beyond Trustworthy AI: Unstable Trust, Mental Health AI, and Proof Infrastructures in Healthcare Governance
#1000788
Record
· ID 274059
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.